0
ARTICLE |

Granulomatous Hepatitis From Hydralazine Therapy

Donald Rice, MD; Claude O. Burdick, MD
Arch Intern Med. 1983;143(5):1077. doi:10.1001/archinte.1983.00350050247057.
Text Size: A A A
Published online

To the Editor.  —Although most hazards of hydralazine hydrochloride therapy are well known, including clinical signs and symptoms resembling lupus erythematosus, the drug continues to be used therapeutically because of its ability to lower BP by a direct effect on peripheral vascular resistance. Among its less well-recognized side effects is serious hepatitis in sensitive individuals. We report herein such a case, where histologic evidence of granulomatous hepatitis was found.

Report of a Case.  —A 51-year-old woman was admitted to the hospital on March 24, 1982, with nausea, fever to 2.2 °C, and dark urine that contained bile. She had begun receiving 2.5 mg/day of metolazone in January and 20 to 80 mg/day of nadolol in February. On March 2, therapy was begun with 25 mg twice daily of hydralazine hydrochloride. Ten days later, the patient began experiencing malaise, with nausea and vomiting following during the next week. Ampicillin sodium, given

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

Correspondence

CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs